Finanzen von Quince Therapeutics Inc (QNCX)QNCXQuince Therapeutics Inc

In the context of the broader market, QNCX competes directly with industry leaders such as QNTM and IGC. With a market capitalization of $31.07M, it holds a significant position in the sector. When comparing efficiency, QNCX's gross margin of N/A stands against QNTM's N/A and IGC's 18.11%. Such benchmarking helps identify whether Quince Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Quince has shown a significant turnaround with a net income of $35,912,000 in Q1 2026 after a series of losses, indicating potential recovery. The current ratio is strong at 14.52, suggesting good short-term financial health.